{
    "4 25 2025": {
        "importantArticles": [
            {
                "headline": "AbbVie (NYSE:ABBV) recently announced its first-quarter earnings, reporting increased sales year-on-year while experiencing a decline in net income and earnings per share. Alongside this, the submission of a Biologics License Application for TrenibotulinumtoxinE marked a significant product announcement. Over the last quarter, AbbVie's stock price moved by 6%, a period that also saw broader market gains driven by a wave of corporate earnings and optimism around potential tariff negotiations...",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.875",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "AbbVie (NYSE:ABBV) Reports US$13 Billion Sales, Submits Application For New Neurotoxin",
                "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-reports-us-175333452.html"
            },
            {
                "headline": "We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other growing dividend stocks. Value stocks are enjoying a rare period of strength amid this year\u2019s broader market downturn. With earnings season approaching, it [\u2026]",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8519",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): One of the Growing Dividend Stocks with Low PE Ratios",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-one-growing-122149162.html"
            },
            {
                "headline": "As part of today's Market Minute, Julie Hyman examines some of the top stories investors are watching. Bitcoin (BTC-USD) climbs above the $95,000 mark as investors weigh macroeconomic uncertainties. AbbVie (ABBV) stock gains after reporting strong first quarter results and lifting its 2025 profit forecast. Phillips 66 (PSX) shares fall after announcing a wider-than-expected loss in the first quarter. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7845",
                "source": "Yahoo Finance Video",
                "ticker": "ABBV",
                "title": "Bitcoin extends rally, AbbVie earnings beat, Phillips 66 miss",
                "url": "https://finance.yahoo.com/video/bitcoin-extends-rally-abbvie-earnings-171137424.html"
            },
            {
                "headline": "Investing.com -- AbbVie Inc (NYSE:ABBV) said Thursday that it is preparing for potential pharmaceutical sector tariffs, warning investors that trade headwinds could impact financial performance later this year. While the company raised its full-year earnings and revenue guidance, executives repeatedly highlighted tariff risk and broader U.S. government disruption as material uncertainties on its earnings call.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8126",
                "source": "Investing.com",
                "ticker": "ABBV",
                "title": "AbbVie warns of tariff exposure, U.S. policy risks while boosting forecast",
                "url": "https://finance.yahoo.com/news/abbvie-warns-tariff-exposure-u-153353444.html"
            },
            {
                "headline": "AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025.",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie Reports First-Quarter 2025 Financial Results",
                "url": "https://finance.yahoo.com/news/abbvie-reports-first-quarter-2025-114300471.html"
            },
            {
                "headline": "AbbVie (ABBV) lifted its full-year outlook on Friday as the biopharmaceutical company recorded first",
                "publication_date": "2025-04-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "ABBV",
                "title": "AbbVie Raises Full-Year Outlook as First-Quarter Results Top Street Estimates",
                "url": "https://finance.yahoo.com/news/abbvie-raises-full-outlook-first-144513452.html"
            }
        ],
        "avgScore": 0.32614000000000015,
        "pctChange": -0.0056648011236314225
    },
    "4 24 2025": {
        "importantArticles": [
            {
                "headline": "Merck (MRK) delivered earnings and revenue surprises of 3.26% and 0.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Merck (MRK) Q1 Earnings and Revenues Top Estimates",
                "url": "https://finance.yahoo.com/news/merck-mrk-q1-earnings-revenues-114007845.html"
            },
            {
                "headline": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here\u2019s what investors should know.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "ABBV",
                "title": "AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect",
                "url": "https://finance.yahoo.com/news/abbvie-abbv-reports-earnings-tomorrow-070109220.html"
            },
            {
                "headline": "The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA",
                "url": "https://finance.yahoo.com/news/buy-stock-healthcare-leaders-q1-230800700.html"
            },
            {
                "headline": "AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3818",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines",
                "url": "https://finance.yahoo.com/news/abbvie-submits-biologics-license-application-123000610.html"
            },
            {
                "headline": "The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA",
                "url": "https://finance.yahoo.com/news/buy-stock-healthcare-leaders-q1-230800700.html"
            },
            {
                "headline": "Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here\u2019s what investors should know.",
                "publication_date": "2025-04-24T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "StockStory",
                "ticker": "ABBV",
                "title": "AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect",
                "url": "https://finance.yahoo.com/news/abbvie-abbv-reports-earnings-tomorrow-070109220.html"
            }
        ],
        "avgScore": -0.143,
        "pctChange": 0.03154628039829696
    },
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings",
                "url": "https://finance.yahoo.com/news/buy-sell-hold-abbv-stock-123400358.html"
            },
            {
                "headline": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-132500143.html"
            },
            {
                "headline": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over the [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Why AbbVie Inc. (ABBV) is Among the Best Stocks That Will Always Grow",
                "url": "https://finance.yahoo.com/news/why-abbvie-inc-abbv-among-142017422.html"
            },
            {
                "headline": "Passive income is essential in retirement, but building a dependable stream isn't easy.  Fortunately, top-tier dividend stocks can do the heavy lifting.  In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7012",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "2 High-Yield Dividend Stocks to Buy for Passive Income",
                "url": "https://finance.yahoo.com/news/2-high-yield-dividend-stocks-123000741.html"
            },
            {
                "headline": "We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over the [\u2026]",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Why AbbVie Inc. (ABBV) is Among the Best Stocks That Will Always Grow",
                "url": "https://finance.yahoo.com/news/why-abbvie-inc-abbv-among-142017422.html"
            },
            {
                "headline": "Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-132500143.html"
            }
        ],
        "avgScore": -0.04317499999999999,
        "pctChange": 0.018751719899485906
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Investing.com",
                "ticker": "ABBV",
                "title": "Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy",
                "url": "https://finance.yahoo.com/news/cantor-initiates-coverage-u-large-134801368.html"
            },
            {
                "headline": "Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics",
                "url": "https://finance.yahoo.com/news/seeking-clues-abbvie-abbv-q1-131519527.html"
            },
            {
                "headline": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for",
                "url": "https://finance.yahoo.com/news/analysts-estimate-pfizer-pfe-report-140058650.html"
            },
            {
                "headline": "President Donald Trump\u2019s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system.  While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a \u201cmajor\u201d tariff on the sector \u201cvery shortly.\u201d  A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.765",
                "source": "Barrons.com",
                "ticker": "ABBV",
                "title": "Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom",
                "url": "https://finance.yahoo.com/m/c624f5c7-9427-3beb-9308-f1a701d24813/eli-lilly-vertex-abbvie-.html"
            },
            {
                "headline": "Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?",
                "url": "https://finance.yahoo.com/news/options-traders-know-something-abbvie-123000258.html"
            },
            {
                "headline": "In the closing of the recent trading day, AbbVie (ABBV) stood at $170.16, denoting a -1.64% change from the preceding trading day.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie (ABBV) Stock Moves -1.64%: What You Should Know",
                "url": "https://finance.yahoo.com/news/abbvie-abbv-stock-moves-1-214533823.html"
            }
        ],
        "avgScore": 0.1019857142857143,
        "pctChange": 0.01881691964225348
    },
    "4 21 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Game Plan for Next Week: 25 Stocks in Focus. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other stocks that Jim Cramer discussed. On Thursday, Jim Cramer, the host of Mad Money, walked viewers through what he described [\u2026]",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings",
                "url": "https://finance.yahoo.com/news/jim-cramer-bullish-abbvie-inc-141550679.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Game Plan for Next Week: 25 Stocks in Focus. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other stocks that Jim Cramer discussed. On Thursday, Jim Cramer, the host of Mad Money, walked viewers through what he described [\u2026]",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings",
                "url": "https://finance.yahoo.com/news/jim-cramer-bullish-abbvie-inc-141550679.html"
            }
        ],
        "avgScore": -0.4939,
        "pctChange": 0.021274065816170334
    },
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-among-innovative-135020761.html"
            },
            {
                "headline": "In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-among-innovative-135020761.html"
            }
        ],
        "avgScore": 0.7184,
        "pctChange": -0.016359337194000602
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend monarchs. Dividend-focused investors are generally well-acquainted with terms like Dividend Aristocrats and Dividend Kings, but many may not be aware [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.714",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-one-best-152051129.html"
            },
            {
                "headline": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let\u2019s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "StockStory",
                "ticker": "ABBV",
                "title": "Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks",
                "url": "https://finance.yahoo.com/news/unpacking-q4-earnings-abbvie-nyse-090605646.html"
            },
            {
                "headline": "AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-abbvie-tjx-083300119.html"
            },
            {
                "headline": "AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-abbvie-tjx-083300119.html"
            },
            {
                "headline": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let\u2019s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "StockStory",
                "ticker": "ABBV",
                "title": "Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks",
                "url": "https://finance.yahoo.com/news/unpacking-q4-earnings-abbvie-nyse-090605646.html"
            },
            {
                "headline": "We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend monarchs. Dividend-focused investors are generally well-acquainted with terms like Dividend Aristocrats and Dividend Kings, but many may not be aware [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.714",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-one-best-152051129.html"
            }
        ],
        "avgScore": 0.3848,
        "pctChange": 0.0076305502869911
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to investors favoring [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7906",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-one-high-114534597.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Top Research Reports for AbbVie, TJX & Charles Schwab",
                "url": "https://finance.yahoo.com/news/top-research-reports-abbvie-tjx-203000671.html"
            },
            {
                "headline": "Merck and AbbVie are included in this Analyst Blog.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog Merck and AbbVie",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-merck-abbvie-105400252.html"
            },
            {
                "headline": "Merck and AbbVie are included in this Analyst Blog.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog Merck and AbbVie",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-merck-abbvie-105400252.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Top Research Reports for AbbVie, TJX & Charles Schwab",
                "url": "https://finance.yahoo.com/news/top-research-reports-abbvie-tjx-203000671.html"
            },
            {
                "headline": "We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other high growth forever dividend stocks. Dividend stocks have trailed the broader market over the past two years, largely due to investors favoring [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7906",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-one-high-114534597.html"
            }
        ],
        "avgScore": 0.3546,
        "pctChange": -0.02895933420588059
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of Long-Term Stock Portfolio: 15 Best Stocks for 15 Years. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks for 15 years. Russell Investments believes that 3 features are defining the market outlook for 2025. These include the elevated level [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Is AbbVie Inc.\u00a0(ABBV) the Best Stock for 15 Years?",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-best-stock-213955811.html"
            },
            {
                "headline": "Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "ABBV vs. MRK: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/abbv-vs-mrk-drug-giant-143700084.html"
            },
            {
                "headline": "AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-abbvies-rinvoq-061700677.html"
            },
            {
                "headline": "AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-abbvies-rinvoq-061700677.html"
            },
            {
                "headline": "Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5106",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "ABBV vs. MRK: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/abbv-vs-mrk-drug-giant-143700084.html"
            },
            {
                "headline": "We recently published a list of Long-Term Stock Portfolio: 15 Best Stocks for 15 Years. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best stocks for 15 years. Russell Investments believes that 3 features are defining the market outlook for 2025. These include the elevated level [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Is AbbVie Inc.\u00a0(ABBV) the Best Stock for 15 Years?",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-best-stock-213955811.html"
            }
        ],
        "avgScore": 0.4553666666666667,
        "pctChange": -0.003719168472553656
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-eu-nod-154700353.html"
            },
            {
                "headline": "ClearBridge Investments, an investment management company, released its \u201cClearBridge Growth Strategy\u201d first quarter 2025 investor letter. A copy of the letter can be downloaded here. First quarter of 2025 witnessed sharp equities sell off due to the shift out of mega caps. There was a relative outperformance of mid cap growth stocks over large and [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Here\u2019s Why Clearbridge Growth Strategy Sold AbbVie (ABBV)",
                "url": "https://finance.yahoo.com/news/why-clearbridge-growth-strategy-sold-141618933.html"
            },
            {
                "headline": "ClearBridge Investments, an investment management company, released its \u201cClearBridge Growth Strategy\u201d first quarter 2025 investor letter. A copy of the letter can be downloaded here. First quarter of 2025 witnessed sharp equities sell off due to the shift out of mega caps. There was a relative outperformance of mid cap growth stocks over large and [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "Here\u2019s Why Clearbridge Growth Strategy Sold AbbVie (ABBV)",
                "url": "https://finance.yahoo.com/news/why-clearbridge-growth-strategy-sold-141618933.html"
            },
            {
                "headline": "EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-eu-nod-154700353.html"
            }
        ],
        "avgScore": 0.6483,
        "pctChange": 0.023136212637444666
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
                "url": "https://finance.yahoo.com/news/investors-heavily-search-abbvie-inc-130016248.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "ABBV",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "ABBV",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know",
                "url": "https://finance.yahoo.com/news/investors-heavily-search-abbvie-inc-130016248.html"
            }
        ],
        "avgScore": 0.07925000000000001,
        "pctChange": 0.004879492121215015
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.  With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue performing long after: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie went public in 2013, splitting from its former parent company, Abbott Laboratories.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8591",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "2 Top Dividend Stocks That Could Set You Up for Life",
                "url": "https://finance.yahoo.com/news/2-top-dividend-stocks-could-110000186.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "ABBV",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            },
            {
                "headline": "The authorisation was based on data from the multicentre Phase III SELECT-GCA trial.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Pharmaceutical Technology",
                "ticker": "ABBV",
                "title": "AbbVie\u2019s upadacitinib gains EU marketing authorisation for GCA",
                "url": "https://finance.yahoo.com/news/abbvie-upadacitinib-gains-eu-marketing-090148754.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "ABBV",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "The authorisation was based on data from the multicentre Phase III SELECT-GCA trial.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Pharmaceutical Technology",
                "ticker": "ABBV",
                "title": "AbbVie\u2019s upadacitinib gains EU marketing authorisation for GCA",
                "url": "https://finance.yahoo.com/news/abbvie-upadacitinib-gains-eu-marketing-090148754.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "ABBV",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            }
        ],
        "avgScore": 0.033574999999999994,
        "pctChange": -0.03136117257721759
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "Investing.com",
                "ticker": "ABBV",
                "title": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
                "url": "https://finance.yahoo.com/news/goldman-turns-cautious-major-pharma-130817424.html"
            },
            {
                "headline": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ\u00ae (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6808",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html"
            },
            {
                "headline": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvies-rinvoq-gets-eu-nod-131500800.html"
            },
            {
                "headline": "Style Box ETF report for SCHD",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?",
                "url": "https://finance.yahoo.com/news/schwab-u-dividend-equity-etf-102008338.html"
            },
            {
                "headline": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvies-rinvoq-gets-eu-nod-131500800.html"
            },
            {
                "headline": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ\u00ae (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6808",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie Announces European Commission Approval of RINVOQ\u00ae (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html"
            }
        ],
        "avgScore": 0.4636,
        "pctChange": 0.02373771925456778
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market volatility from tariff uncertainties that saw the Dow Jones drop over 900 points on certain days. As other sectors of the market faced declines, AbbVie's focus on new product...",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting",
                "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-showcases-cancer-173157102.html"
            },
            {
                "headline": "AbbVie (NYSE:ABBV) has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in cancer treatment. This aligns with AbbVie's upward price move of 4% over the last quarter, despite wider market volatility from tariff uncertainties that saw the Dow Jones drop over 900 points on certain days. As other sectors of the market faced declines, AbbVie's focus on new product...",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1027",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting",
                "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-showcases-cancer-173157102.html"
            }
        ],
        "avgScore": -0.1027,
        "pctChange": -0.058322204832492154
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie (ABBV) Stock Moves -1.73%: What You Should Know",
                "url": "https://finance.yahoo.com/news/abbvie-abbv-stock-moves-1-214515437.html"
            },
            {
                "headline": "In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie (ABBV) Stock Moves -1.73%: What You Should Know",
                "url": "https://finance.yahoo.com/news/abbvie-abbv-stock-moves-1-214515437.html"
            }
        ],
        "avgScore": 0.0,
        "pctChange": -0.0021930057580403966
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice.  Not every long-term investment will turn out that way, but investing a modest amount of money in growth stocks and letting it sit can be your best financial move.  Retirees on the lookout for some reliable dividend stocks can find plenty of attractive buying opportunities in the markets today.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9505",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
                "url": "https://finance.yahoo.com/news/3-high-yielding-dividend-stocks-130000935.html"
            },
            {
                "headline": "AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Reuters",
                "ticker": "ABBV",
                "title": "AbbVie cuts 2025 profit forecast on acquisition expenses",
                "url": "https://finance.yahoo.com/news/abbvie-cuts-2025-profit-forecast-203448175.html"
            },
            {
                "headline": "AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Reuters",
                "ticker": "ABBV",
                "title": "AbbVie cuts 2025 profit forecast on acquisition expenses",
                "url": "https://finance.yahoo.com/news/abbvie-cuts-2025-profit-forecast-203448175.html"
            },
            {
                "headline": "\"Buy and hold\" is a simple strategy for investors, but it can be a hard one to stick to in actual practice.  Not every long-term investment will turn out that way, but investing a modest amount of money in growth stocks and letting it sit can be your best financial move.  Retirees on the lookout for some reliable dividend stocks can find plenty of attractive buying opportunities in the markets today.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9505",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About",
                "url": "https://finance.yahoo.com/news/3-high-yielding-dividend-stocks-130000935.html"
            }
        ],
        "avgScore": 0.69545,
        "pctChange": -0.07280301922898035
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7713",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?",
                "url": "https://finance.yahoo.com/news/abbvie-stock-rises-16-date-140600657.html"
            },
            {
                "headline": "Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7713",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?",
                "url": "https://finance.yahoo.com/news/abbvie-stock-rises-16-date-140600657.html"
            }
        ],
        "avgScore": 0.7713,
        "pctChange": -0.01730100637967199
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8834",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "High Growth Tech Stocks To Watch In The US April 2025",
                "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-110804833.html"
            },
            {
                "headline": "Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and resilience amidst fluctuating market conditions.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8834",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "High Growth Tech Stocks To Watch In The US April 2025",
                "url": "https://finance.yahoo.com/news/high-growth-tech-stocks-watch-110804833.html"
            }
        ],
        "avgScore": 0.8834,
        "pctChange": -0.005235873366388621
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend aristocrats with a high yield. Dividend Aristocrats are the companies that have raised their payouts for 25 consecutive years [\u2026]",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Insider Monkey",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-among-best-232508103.html"
            },
            {
                "headline": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6666",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
                "url": "https://finance.yahoo.com/news/want-1-million-retirement-3-085300048.html"
            },
            {
                "headline": "By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Zacks Small Cap Research",
                "ticker": "ABBV",
                "title": "MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon\u2026",
                "url": "https://finance.yahoo.com/news/mtva-phase-1-part-2-141600803.html"
            },
            {
                "headline": "AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie to Host First-Quarter 2025 Earnings Conference Call",
                "url": "https://finance.yahoo.com/news/abbvie-host-first-quarter-2025-120000473.html"
            },
            {
                "headline": "By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 MetaVia Inc. (NASDAQ:MTVA) is currently conducting a Phase 1 clinical trial of DA-1726 in patients with obesity. In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the trial. A total of 45",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Zacks Small Cap Research",
                "ticker": "ABBV",
                "title": "MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon\u2026",
                "url": "https://finance.yahoo.com/news/mtva-phase-1-part-2-141600803.html"
            },
            {
                "headline": "Building a retirement portfolio of $1 million or more is within reach for many Americans.  AbbVie (NYSE: ABBV) is a great example of a company that has proved such a capability.  A few years ago, some wondered what would happen to AbbVie after key patents expired for Humira, the company's top-selling drug.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6666",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.",
                "url": "https://finance.yahoo.com/news/want-1-million-retirement-3-085300048.html"
            }
        ],
        "avgScore": 0.519875,
        "pctChange": -0.015511670429519404
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "Despite a significant revenue drop, CollPlant Biotechnologies Ltd (CLGN) focuses on promising collaborations and innovative product developments to drive future growth.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8137",
                "source": "GuruFocus.com",
                "ticker": "ABBV",
                "title": "CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...",
                "url": "https://finance.yahoo.com/news/collplant-biotechnologies-ltd-clgn-q4-070159846.html"
            },
            {
                "headline": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.34",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-attracting-investor-130016421.html"
            },
            {
                "headline": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
                "url": "https://finance.yahoo.com/news/vktx-finishes-enrolment-mid-stage-123100379.html"
            },
            {
                "headline": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
                "url": "https://finance.yahoo.com/news/vktx-finishes-enrolment-mid-stage-123100379.html"
            },
            {
                "headline": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.34",
                "source": "Zacks",
                "ticker": "ABBV",
                "title": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
                "url": "https://finance.yahoo.com/news/abbvie-inc-abbv-attracting-investor-130016421.html"
            },
            {
                "headline": "Despite a significant revenue drop, CollPlant Biotechnologies Ltd (CLGN) focuses on promising collaborations and innovative product developments to drive future growth.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8137",
                "source": "GuruFocus.com",
                "ticker": "ABBV",
                "title": "CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...",
                "url": "https://finance.yahoo.com/news/collplant-biotechnologies-ltd-clgn-q4-070159846.html"
            }
        ],
        "avgScore": 0.38456666666666667,
        "pctChange": 0.012677489525255046
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn in the broader market, with major indexes like the S&P 500 and Nasdaq seeing declines of 1% and 2% respectively, AbbVie managed an 11.86% increase in its stock price over the last quarter. This period also included critical...",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8625",
                "source": "Simply Wall St.",
                "ticker": "ABBV",
                "title": "AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip",
                "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-showcases-oncology-174606580.html"
            },
            {
                "headline": "If markets remain rocky, either because of the Trump administration\u2019s trade war or soft economic data, the aristocrats could continue to outperform.  \u201cOur favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to \u2018hide\u2019 in the event of an economic slowdown or recessionary environment,\u201d he wrote.  The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the  often known by its ticker, NOBL.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Barrons.com",
                "ticker": "ABBV",
                "title": "These Dividend Stocks Can Protect You From the Next Market Drop",
                "url": "https://finance.yahoo.com/m/7d333c75-ac96-3e68-aa51-35c647e66bec/these-dividend-stocks-can.html"
            },
            {
                "headline": "The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest point in more than a decade.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "Investopedia",
                "ticker": "ABBV",
                "title": "S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook",
                "url": "https://finance.yahoo.com/news/p-500-gains-losses-today-211117025.html"
            },
            {
                "headline": "AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30, 2025. Presentations include data from novel investigational molecules, ABBV-969 and ABBV-514, across a range of hard-to-treat tumor types.1,2 Additionally, new insights on treatment resistance and novel biomarker identification based on real-world-data analyses are to be prese",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "PR Newswire",
                "ticker": "ABBV",
                "title": "AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025",
                "url": "https://finance.yahoo.com/news/abbvie-showcases-early-pipeline-scientific-123000731.html"
            },
            {
                "headline": "AbbVie's shares  dropped off a cliff  in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition.  Investors were worried the company spent nearly $9 billion for nothing, which is understandable.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "ABBV",
                "title": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
                "url": "https://finance.yahoo.com/news/2-dividend-stocks-defying-market-103000309.html"
            },
            {
                "headline": "The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest point in more than a decade.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1779",
                "source": "Investopedia",
                "ticker": "ABBV",
                "title": "S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook",
                "url": "https://finance.yahoo.com/news/p-500-gains-losses-today-211117025.html"
            }
        ],
        "avgScore": 0.22261999999999998,
        "pctChange": 0.007054150082361787
    },
    "coef": -0.28441558441558445,
    "avgCoef": 0.003599378506637638,
    "similar": {
        "ABEV": 0.35737499422108393,
        "NKE": 0.2675324675324675,
        "KO": 0.15454545454545454,
        "GILD": 0.14155844155844155
    }
}